Ginkgo Bioworks Holdings(DNA)
$10.25-1.76 (-14.65%)
DNA
Ginkgo Bioworks Holdings stock kpis
$10.25
At close:-1.76 (-14.65%)
Want to see DNA full AI Analyst Report?
Revenue by Segment
Breaks down income by business area, showing which segments are most lucrative and where there might be room for expansion or increased focus.
Ginkgo has shifted from pandemic-era biosecurity sales to an engineering-led model: Biosecurity Products disappear after 2023 and Services have fallen from earlier peaks to a much lower, steadier run rate, while Cell Engineering now supplies most revenue and shows lumpy, milestone-driven spikes. That makes top-line growth more volatile and dependent on the timing of partnerships and program milestones—investors should focus on booked contract mix and recurring revenue to assess whether recent spikes translate into sustainable growth.
DNA Revenue by Segment
| Date | Cell Engineering | Biosecurity Products | Biosecurity Services |
|---|---|---|---|
| Jun 30, 2026 | $20.16M | $0.00 | $0.00 |
| Mar 31, 2026 | $19.47M | $0.00 | $0.00 |
| Dec 31, 2025 | $26.00M | $0.00 | $7.39M |
| Sep 30, 2025 | $29.38M | $0.00 | $9.46M |
| Jun 30, 2025 | $39.13M | $0.00 | $10.47M |
| Mar 31, 2025 | $38.23M | $0.00 | $10.09M |
| Dec 31, 2024 | $34.79M | $0.00 | $9.06M |
| Sep 30, 2024 | $75.09M | $0.00 | $13.96M |
| Jun 30, 2024 | $36.20M | $0.00 | $20.00M |
| Mar 31, 2024 | $27.89M | $0.00 | $10.05M |
| Dec 31, 2023 | $26.98M | $0.00 | $7.78M |
| Sep 30, 2023 | $37.18M | $6.50M | $11.76M |
| Jun 30, 2023 | $45.28M | $10.79M | $24.50M |
| Mar 31, 2023 | $34.10M | $11.67M | $34.94M |
| Dec 31, 2022 | $53.26M | $12.43M | $32.60M |
| Sep 30, 2022 | $24.68M | $5.19M | $36.53M |
| Jun 30, 2022 | $44.24M | $3.89M | $96.49M |
| Mar 31, 2022 | $21.49M | $13.95M | $132.97M |
| Dec 31, 2021 | $34.16M | $8.42M | $105.92M |
| Sep 30, 2021 | $34.74M | $8.49M | $34.83M |
| Jun 30, 2021 | $21.53M | $355.00K | $21.69M |
| Mar 31, 2021 | $22.50M | $5.78M | $15.82M |
